[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492024":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":105,"collaborators":26,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":26,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":26,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"GC Biopharma Corp","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Undiluted intravenous infusion of I.V.-Hepabig inj","EXPERIMENTAL","Undiluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit within approximately 30 minutes",[13],"Biological: Undiluted I.V.-Hepabig inj(GC5103)",{"label":15,"type":16,"description":17,"interventionNames":18},"Diluted intravenous infusion of I.V.-Hepabig inj","ACTIVE_COMPARATOR","Diluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit into Dextrose 5% in water within approximately 1 hour",[19],"Biological: Diluted I.V.-Hepabig inj(GC5103)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","Undiluted I.V.-Hepabig inj(GC5103)","undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Diluted I.V.-Hepabig inj(GC5103)","Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Jiyoung Sin","CONTACT","82-(0)31-260-9570","jiyoung.sin@gccorp.com",[38,51,60,69,78,87,93,99],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":26,"cosmosGeoPoint":45,"geoPoint":50,"contacts":26},"National Cancer Center","RECRUITING","Goyang-si","Gyeonggi-do","10408","South Korea",{"type":46,"coordinates":47},"Point",[48,49],126.835,37.65639,{"lat":49,"lon":48},{"facility":52,"status":40,"city":53,"state":42,"zip":54,"country":44,"countryCode":26,"cosmosGeoPoint":55,"geoPoint":59,"contacts":26},"Ajou University Medical Center","Suwon","16499",{"type":46,"coordinates":56},[57,58],127.00889,37.29111,{"lat":58,"lon":57},{"facility":61,"status":40,"city":62,"state":62,"zip":63,"country":44,"countryCode":26,"cosmosGeoPoint":64,"geoPoint":68,"contacts":26},"Asan Medical Center","Seoul","05505",{"type":46,"coordinates":65},[66,67],126.9784,37.566,{"lat":67,"lon":66},{"facility":70,"status":40,"city":71,"state":26,"zip":72,"country":44,"countryCode":26,"cosmosGeoPoint":73,"geoPoint":77,"contacts":26},"Inje University Haeundae Paik Hospital","Busan","48108",{"type":46,"coordinates":74},[75,76],129.03004,35.10168,{"lat":76,"lon":75},{"facility":79,"status":40,"city":80,"state":26,"zip":81,"country":44,"countryCode":26,"cosmosGeoPoint":82,"geoPoint":86,"contacts":26},"Chungnam National University Hospital","Daejeon","35015",{"type":46,"coordinates":83},[84,85],127.38493,36.34913,{"lat":85,"lon":84},{"facility":88,"status":40,"city":62,"state":26,"zip":89,"country":44,"countryCode":26,"cosmosGeoPoint":90,"geoPoint":92,"contacts":26},"Seoul National University Hospital","03080",{"type":46,"coordinates":91},[66,67],{"lat":67,"lon":66},{"facility":94,"status":40,"city":62,"state":26,"zip":95,"country":44,"countryCode":26,"cosmosGeoPoint":96,"geoPoint":98,"contacts":26},"Severance Hospital","03722",{"type":46,"coordinates":97},[66,67],{"lat":67,"lon":66},{"facility":100,"status":40,"city":62,"state":26,"zip":101,"country":44,"countryCode":26,"cosmosGeoPoint":102,"geoPoint":104,"contacts":26},"Samsung Medical Center","06351",{"type":46,"coordinates":103},[66,67],{"lat":67,"lon":66},{"type":106,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100492024","phase-3-a-study-to-investigate-the-safety-and-efficacy-of-undiluted-intravenous-infusion-of-iv-hepabig-inj-100492024",false,"NCT05686759","A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.","A Phase 3b Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. in Post-liver Transplant Patients","Inclusion Criteria:\n\n1. Aged ≥18 and \\\u003C65 years at the time of signing the consent form\n2. Subjects who had history of liver transplantation due to HBV-related end-stage liver disease such as cirrhosis, liver cancer and fulminant hepatic failure and received treatment for prevent hepatitis B recurrence\n3. HBsAg(+) before liver transplantation\n4. Subjects who have been received I.V.-Hepabig inj more than 3 times dose of 10,000International Unit\u002F4weeks regimen\n\nExclusion Criteria:\n\n1. Subject with history of anaphylaxis to any component of the investigational product\n2. Pregnant or breast-feeding women\n3. Deficiency of Immunoglobulin A\n4. Clinically significant renal diseases (serum creatinine \\>2.0mg\u002FdL, anuria, renal failure or on dialysis at screening)\n5. Hemophilia\n6. Co-infection with Hepatitis A Virus, Hepatitis C Virus, or Human Immunodeficiency Virus\n7. Subject with history of malignancy within the last 5 years (excluding primary liver cancer)\n8. Subject received estrogen or hormone replacement therapy within 3 months before screening\n9. HBsAg or HBeAg or HBV DNA positive at screening\n10. Anti HBs titer less than below criteria at screening \\\u003C150 IU\u002FL for subject whose HBeAg and HBV DNA were negative(-) before liver transplantation \\>500 IU\u002FL for subject whose HBeAg or HBV DNA were positive(+) before liver transplantation\n11. Subject with history of drug abuse\n12. Participated in another clinical study within 30 days (relative to the last dose of investigational product) before screening\n13. Subject who are determined disqualified to join clinical trials by investigator","ALL","18 Years","64 Years",{"count":118,"type":119},105,"ESTIMATED","INTERVENTIONAL",[122],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients",[125],"Hepatitis B",[125,127,128,129],"Liver Transplantation","Hepatitis B Immunoglobulin","Liver Diseases","2025-06-18",{"date":132,"type":133},"2025-06-25","ACTUAL",{"date":135,"type":133},"2023-04-13",{"date":137,"type":119},"2026-06-30",{"name":5,"class":6},8]